Silence Therapeutics plc

Management Reports • May 11, 2015

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 7629M

Silence Therapeutics PLC

11 May 2015

11 May 2015

Silence Therapeutics plc

Notice of AGM and posting of annual report and accounts

Silence Therapeutics plc, AIM: SLN, ("Silence" or "the Company"), a leader in the development and delivery of novel RNA therapeutics will be holding its AGM at 10am on Monday, 1 June 2015 at the offices of Silence Therapeutics, 1 Lyric Square, London, W6 0NB. Notice of the AGM can also be found on the website in the Investor Relations section.

The Company has posted to shareholders its annual report and accounts for the year ended 31 December 2014. The annual report can also be found online at:

http://silence-therapeutics.com/investors-media/investor-relations/#ResultsReportsPresentations

Enquiries:

Silence Therapeutics plc	+44 (0)20 3700 9711
Timothy Freeborn, Finance Director and Company Secretary
Rozi Morris, Communications Manager
Canaccord Genuity Limited (Nominated Adviser and Joint Broker)	+44 (0)20 7523 8350
Dr Julian Feneley/Cara Griffiths/Henry Fitzgerald-O'Connor
Peel Hunt LLP (Joint Broker)	+44 (0)20 7418 8900
James Steel/ Oliver Jackson

About Silence Therapeutics (www.silence-therapeutics.com) 

Silence Therapeutics is a leading RNA therapeutics company. It has developed proprietary modifications to improve the robustness of RNA sequences together with advanced liposomal chemistries to enhance the delivery of its therapeutics. Its technology can selectively silence or replace the expression of any gene in the genome, modulating expression up as well as down in a variety of organs and cell types, in vivo. This allows the development of therapeutics for diseases with high unmet clinical need. Silence's technology is currently in the clinic in a Phase 2a pancreatic cancer trial.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NOASFDSUFFISESI